Lenalidomide Sandoz 20 Mg Hard Capsules

Lenalidomide, the active ingredient in Lenalidomide Sandoz 20 Mg Hard Capsules, is an immunomodulatory drug (IMiD) presented as a 20 mg hard capsule for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Sandoz 20 Mg Hard Capsules as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related disorders.

- Multiple myeloma: improves progression‑free survival and overall response when combined with dexamethasone or other agents. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Mantle cell lymphoma: contributes to disease control as part of combination therapy in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Diarrhea: loose stools of mild to moderate severity. - Rash: skin eruptions ranging from mild erythema to pruritic lesions. - Nausea: occasional upset stomach or vomiting.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating therapy, several safety considerations should be reviewed.

- Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thromboembolic prophylaxis: assess need for anticoagulation in patients with additional risk factors. - Renal impairment: monitor renal function closely and consider dose modification in severe dysfunction. - Hepatic impairment: regular liver‑function testing is advised. - Infection monitoring: watch for signs of infection due to neutropenia. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lenalidomide can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower lenalidomide exposure. - Anticoagulants (e.g., warfarin): concurrent use can increase thrombotic risk and requires careful monitoring.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma concentrations. - Immunosuppressants (e.g., cyclosporine): may enhance immunomodulatory effects. - Live vaccines: should be avoided because lenalidomide alters immune response.